Last reviewed 2026-04-23 · How we verify

TVP-1012

TVP-1012 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).

TVP-1012 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1). Used for Multiple sclerosis.

At a glance

Mechanism of action

S1PR1 is a key regulator of lymphocyte trafficking and homing. By targeting S1PR1, TVP-1012 aims to reduce lymphocyte infiltration into tissues, which is a hallmark of autoimmune diseases.

Approved indications

• Multiple sclerosis

Common side effects

• Headache
• Nausea
• Diarrhea

Key clinical trials

• A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants (PHASE3)
• A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants (PHASE3)
• A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants (PHASE2, PHASE3)
• A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients (PHASE3)
• Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease (PHASE4)
• Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease (PHASE4)
• Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) (PHASE2)
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TVP-1012 CI brief — competitive landscape report
• TVP-1012 updates RSS · CI watch RSS
• Takeda portfolio CI